These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 3390580

  • 1. New orally active alpha-ketohydroxy pyridine chelators for the treatment of iron overload.
    Kontoghiorghes GJ.
    Birth Defects Orig Artic Ser; 1988; 23(5B):97-103. PubMed ID: 3390580
    [No Abstract] [Full Text] [Related]

  • 2. Orally active alpha-ketohydroxypyridine iron chelators: studies in mice.
    Kontoghiorghes GJ.
    Mol Pharmacol; 1986 Dec; 30(6):670-3. PubMed ID: 3785144
    [Abstract] [Full Text] [Related]

  • 3. The study of iron mobilisation from transferrin using alpha-ketohydroxy heteroaromatic chelators.
    Kontoghiorghes GJ.
    Biochim Biophys Acta; 1986 Jan 30; 869(2):141-6. PubMed ID: 3942757
    [Abstract] [Full Text] [Related]

  • 4. Iron chelation, quo vadis?
    Nick H.
    Curr Opin Chem Biol; 2007 Aug 30; 11(4):419-23. PubMed ID: 17644021
    [Abstract] [Full Text] [Related]

  • 5. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
    Lim CK, Kalinowski DS, Richardson DR.
    Mol Pharmacol; 2008 Jul 30; 74(1):225-35. PubMed ID: 18424550
    [Abstract] [Full Text] [Related]

  • 6. Orally active alpha-ketohydroxy pyridine iron chelators intended for clinical use: in vivo studies in rabbits.
    Kontoghiorghes GJ, Hoffbrand AV.
    Br J Haematol; 1986 Apr 30; 62(4):607-13. PubMed ID: 3964556
    [Abstract] [Full Text] [Related]

  • 7. PCTH: a novel orally active chelator for the treatment of iron overload disease.
    Lovejoy DB, Kalinowski D, Bernhardt PV, Richardson DR.
    Hemoglobin; 2006 Apr 30; 30(1):93-104. PubMed ID: 16540421
    [Abstract] [Full Text] [Related]

  • 8. N-phthaloyl-glycine-hydroxamic acid as serum iron chelator in rats.
    Matijević-Sosa J, Samarzija I, Honović L, Jurisić B.
    Acta Pharm; 2008 Jun 30; 58(2):231-6. PubMed ID: 18515233
    [Abstract] [Full Text] [Related]

  • 9. New synthetic approach and iron chelating studies of 1-alkyl-2-methyl-3-hydroxypyrid-4-ones.
    Kontoghiorghes GJ, Sheppard L, Chambers S.
    Arzneimittelforschung; 1987 Oct 30; 37(10):1099-102. PubMed ID: 3435580
    [Abstract] [Full Text] [Related]

  • 10. Alternative treatment paradigm for thalassemia using iron chelators.
    Szuber N, Buss JL, Soe-Lin S, Felfly H, Trudel M, Ponka P.
    Exp Hematol; 2008 Jul 30; 36(7):773-85. PubMed ID: 18456387
    [Abstract] [Full Text] [Related]

  • 11. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator.
    Donovan JM, Plone M, Dagher R, Bree M, Marquis J.
    Ann N Y Acad Sci; 2005 Jul 30; 1054():492-4. PubMed ID: 16339704
    [Abstract] [Full Text] [Related]

  • 12. Tritrichomonas foetus: iron acquisition from lactoferrin and transferrin.
    Tachezy J, Kulda J, Bahníková I, Suchan P, Rázga J, Schrével J.
    Exp Parasitol; 1996 Jul 30; 83(2):216-28. PubMed ID: 8682190
    [Abstract] [Full Text] [Related]

  • 13. Effect of a prolonged superoxide flux on transferrin and ferritin.
    Paul T.
    Arch Biochem Biophys; 2000 Oct 15; 382(2):253-61. PubMed ID: 11068877
    [Abstract] [Full Text] [Related]

  • 14. Iron metabolism and the effect of iron chelators in rat hepatoma cells.
    Baker E, Lloyd DA, Morgan EH, Yeoh GC.
    Birth Defects Orig Artic Ser; 1988 Oct 15; 23(5B):89-95. PubMed ID: 3390578
    [No Abstract] [Full Text] [Related]

  • 15. Selection of a new generation of orally active alpha-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload.
    Kontoghiorghes GJ, Barr J, Nortey P, Sheppard L.
    Am J Hematol; 1993 Apr 15; 42(4):340-9. PubMed ID: 8493983
    [Abstract] [Full Text] [Related]

  • 16. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
    Devanur LD, Evans RW, Evans PJ, Hider RC.
    Biochem J; 2008 Jan 15; 409(2):439-47. PubMed ID: 17919118
    [Abstract] [Full Text] [Related]

  • 17. In vivo and in vitro effects of 3-hydroxypyridin-4-one chelators on murine hemopoiesis.
    Hoyes KP, Jones HM, Abeysinghe RD, Hider RC, Porter JB.
    Exp Hematol; 1993 Jan 15; 21(1):86-92. PubMed ID: 8417963
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic potential of iron chelators in diseases associated with iron mismanagement.
    Weinberg ED.
    J Pharm Pharmacol; 2006 May 15; 58(5):575-84. PubMed ID: 16640825
    [Abstract] [Full Text] [Related]

  • 19. Can iron chelators influence the progression of atherosclerosis?
    Marx JJ, Kartikasari AE, Georgiou NA.
    Hemoglobin; 2008 May 15; 32(1-2):123-34. PubMed ID: 18274990
    [Abstract] [Full Text] [Related]

  • 20. Biologic screens for iron chelators.
    Baker E.
    Birth Defects Orig Artic Ser; 1988 May 15; 23(5B):49-61. PubMed ID: 3291970
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.